Anti-Kir2.1/KCNJ2 Antibody

Inward rectifier potassium channel 2, IRK1, HIRK1, LQT7, SQT3
    Cat #: APC-026
    Alternative Name Inward rectifier potassium channel 2, IRK1, HIRK1, LQT7, SQT3
  • Lyophilized Powder
  • Antigen Incl.
  • Type: Polyclonal
    Host: Rabbit
    Reactivity: h, m, r
    Immunogen
    • Peptide (C)NGVPESTSTDTPPDIDLHN, corresponding to amino acid residues 392-410 of human Kir2.1 (Accession P48049). Intracellular, C-terminal part.
    • Anti-Kir2.1/KCNJ2 Antibody
    Gene ID 3759
    Peptide confirmation Confirmed by amino acid analysis and mass spectrometry.
    Homology Rabbit, bovine, pig, guinea pig - identical; rat, mouse - 17/19 amino acid residues identical; chicken - 15/19 amino acid residues identical.
    RRID AB_2040107.
    Purity Affinity purified on immobilized antigen.
    Form Lyophilized powder. Reconstituted antibody contains phosphate buffered saline (PBS), pH 7.4, 1% BSA, 0.05% NaN3.
    Isotype Rabbit IgG.
    Storage before reconstitution The antibody ships as a lyophilized powder at room temperature. Upon arrival, it should be stored at -20°C.
    Reconstitution 25 µl, 50 μl or 0.2 ml double distilled water (DDW), depending on the sample size.
    Antibody concentration after reconstitution 0.6 mg/ml.
    Storage after reconstitution The reconstituted solution can be stored at 4°C for up to 1 week. For longer periods, small aliquots should be stored at -20°C. Avoid multiple freezing and thawing. Centrifuge all antibody preparations before use (10000 x g 5 min).
    Negative control antigen storage before reconstitution Lyophilized powder can be stored intact at room temperature for 2 weeks. For longer periods, it should be stored at -20°C.
    Negative control antigen reconstitution 100 µl double distilled water (DDW).
    Negative control antigen storage after reconstitution -20°C.
    Preadsorption Control 1 μg peptide per 1 μg antibody.
    Standard quality control of each lot Western blot analysis.
    Applications: ic, if, ifc, ih, ip, wb
    Western blot
    • Anti-Kir2.1/KCNJ2 Antibody
      Western blot analysis of rat heart (lanes 1 and 3) and rat brain (lanes 2 and 4) membranes:
      1,2. Anti-Kir2.1/KCNJ2 Antibody (#APC-026), (1:200).
      3,4. Anti-Kir2.1/KCNJ2 Antibody, preincubated with the negative control antigen.
    Immunoprecipitation
    • Transfected HEK 293 cell lysate (Preisig Muller, R. et al. (2002) Proc. Natl. Acad. Sci. U.S.A. 99, 7774.).
    Immunohistochemistry
    • Rat brain sections.
    Immunocytochemistry
    • Mouse ventricular myocytes (1:200) (Clark, R.B. et al. (2001) J. Physiol. 537, 979.).
    Indirect flow cytometry
    • Human bladder urothelial cells (BUC) (Sun, Y. et al. (2007) Am. J. Physiol. 292, C106.).
    References
    1. Kubo, Y. et al. (1993) Nature 362, 127.
    2. Nichols, C.G. et al. (1996) Circ. Res. 78, 1.
    3. Plaster, N.M. et al. (2001) Cell 105, 511.
    Scientific background

    Kir2.1 is a member of the family of inward rectifying K+ channels. The family includes 15 members that are structurally and functionally different from the voltage-dependent K+ channels.

    The family’s topology consists of two transmembrane domains that flank a single and highly conserved pore region with intracellular N- and C-termini. As is the case for the voltage-dependent K+ channels the functional unit for the Kir channels is composed of four subunits that can assemble as either homo- or heterotetramers.

    Kir channels are characterized by a K+ efflux that is limited by depolarizing membrane potentials thus making them essential for controlling resting membrane potential and K+ homeostasis.

    Kir2.1 is a member of the Kir2.x subfamily that includes four members (Kir2.1- Kir2.4) that are characterized by strong inward rectification and high constitutive activity.

    Kir2.1 is expressed in a variety of tissues including the heart, brain, vascular smooth muscle cells and skeletal muscles.

    In the heart, Kir2.1 is a molecular component of the IK1 current that is responsible for setting the resting membrane potential, preventing membrane hyperpolarization due to Na+ pump activity, influencing propagation velocity, altering the electrical space constant, and promoting late phase repolarization.2 In fact, mutations in Kir2.1 channels have been linked to a form of long QT syndrome (LQT7) known as Andersen's syndrome that is characterized by cardiac arrhythmias, periodic paralysis, and dysmorphic features.3

    Application key:

    CBE- Cell-based ELISA, FC- Flow cytometry, ICC- Immunocytochemistry, IE- Indirect ELISA, IF- Immunofluorescence, IFC- Indirect flow cytometry, IHC- Immunohistochemistry, IP- Immunoprecipitation, LCI- Live cell imaging, N- Neutralization, WB- Western blot

    Species reactivity key:

    H- Human, M- Mouse, R- Rat
    Image & Title: Anti-Kir2.1 (KCNJ2) Antibody
    Expression of Kir2.1 in canine myocytes.
    Immunocytochemical staining of canine myocytes using Anti-Kir2.1/KCNJ2 Antibody (#APC-026). Kir2.1 staining (green) is detected in both ventricle (V) and atria (A). Kir2.1 staining is eradicated when antibody is incubated with the peptide antigen (C and F).Adapted from Melnyk, P. et al. (2002) Am. J. Physiol. 283, 1123. with permission of The American Physiological Society.
    Last update: 27/02/2020

    Alomone Labs is pleased to offer a highly specific antibody directed against an epitope of human Kir2.1 channel. Anti-Kir2.1/KCNJ2 Antibody (#APC-026) can be used in western blot, immunoprecipitation, immunocytochemistry, immunohistochemistry, and flow cytometry applications. It has been designed to recognize Kir2.1 from human, rat, and mouse samples.

    For research purposes only, not for human use

    Applications

    Specifications

    Scientific Background

    Citations

    Citations
    Published figures using this product
    • Anti-Kir2.1/KCNJ2 Antibody
      Expression of Kir2.1 in human U-251 MG cells.
      A. Immunocytochemical staining of human astrocytoma U-251 MG cells expressing WT or K346T channels using Anti-Kir2.1/KCNJ2 Antibody (#APC-026) (red). WT channels are localized in perinuclear vesicles (short arrows in upper panel) and occasionally at plasma membranes (long arrows in upper panel). Mutated channels are mainly expressed at plasma membranes (long arrows in lower panel). B. WB analysis of membrane (MEM) and cytosolic (CYT) proteins derived from WT or K346T Kir2.1-expressing cells using Anti-Kir2.1/KCNJ2 Antibody. D. Densitometric analysis of protein bands from four independent experiments (mean ± SEM, P < 0.05).
      Adapted from Ambrosini, E. et al. (2014) with permission of Oxford University Press.
    • Anti-Kir2.1/KCNJ2 Antibody
      Expression of Kir2.1 and Kir2.3 channels in Lamina I pacemaker cells.
      Immunohistochemical staining of rat spinal cord sections using Lamina I pacemaker using Anti-Kir2.1/KCNJ2 Antibody (#APC-026) and Anti-Kir2.3 (KCNJ4) Antibody (#APC-032). Confocal images of representative biocytin-filled pacemaker neurons (red) processed for Kir (green). Merged images demonstrate that immunoreactive puncta for Kir2.1 and Kir2.3 (yellow; inset) are localized to identified pacemaker neurons within lamina I of the neonatal spinal cord (right). Scale bars: 10 μm; inset, 2 μm.
      Adapted from Li, J. et al. (2013) with permission of The Society for Neuroscience.
    Western blot citations
    1. Human THP-1 cells.
      Kim, K.S. et al. (2015) J. Immunol. 195, 3345.
    2. Mouse activated macrophages (BMDM cells).
      Moreno, C. et al. (2013) J. Immunol. 191, 6136.
    Immunoprecipitation citations
    1. Transfected HEK 293 cell lysate.
      Preisig Muller, R. et al. (2002) Proc. Natl. Acad. Sci. U.S.A. 99, 7774.
    Immunohistochemistry citations
    1. Rat retina sections (1:100).
      Li, Q. et al. (2017) Brain Struct. Funct. 222, 813.
    2. Rat dorsal root ganglia and spinal cord sections (1:200).
      Murata, Y. et al. (2016) Neurosci. Lett. 617, 59.
    3. Rat spinal cord sections (1:200).
      Li, J. et al. (2013) J. Neurosci. 33, 3352.
    4. Rat heart sections (1:20).
      Atkinson, A.J. et al. (2013) J. Am. Heart Assoc. 2, e000246.
    Immunocytochemistry citations
    1. HEK 293 transfected cells (1:200).
      Murata, Y. et al. (2016) Neurosci. Lett. 617, 59.
    2. Human THP-1 cells (1:200).
      Kim, K.S. et al. (2015) J. Immunol. 195, 3345.
    3. Human astrocytoma U-251 MG cells.
      Ambrosini, E. et al. (2014) Hum. Mol. Genet. 23, 4875.
    4. Mouse microglia (1:100).
      Muessel, M.J. et al. (2013) Glia 61, 1620.
    5. Mouse activated macrophages (BMDM cells).
      Moreno, C. et al. (2013) J. Immunol. 191, 6136.
    6. Mouse cardiomyocytes (1:200).
      Fujiwara, M. et al. (2011) PLoS One 6, e16734.
    7. Canine myocytes.
      Melnyk, P. et al. (2002) Am. J. Physiol. 283, 1123.
    8. Mouse ventricular myocytes (1:200).
      Clark, R.B. et al. (2001) J. Physiol. 537.3, 979.
    Indirect flow cytometry citations
    1. Human bladder urothelial cells (BUC).
      Sun, Y. et al. (2007) Am. J. Physiol. 292, C106.
    More product citations
    1. Askar, S.F. et al. (2013) Cardiovasc. Res. 97, 171.
    2. Bonilla, I.M. et al. (2012) J. Appl. Physiol. 113, 1772.
    3. Hong, M. et al. (2012) J. Biol. Chem. 287, 41258.
    4. Tajada, S. et al. (2012) J. Physiol. 590, 6075.
    5. Eberhardt, C. et al. (2011) Glia 59, 697.
    6. Yamazaki, D. et al. (2011) Am. J. Physiol. 300, C75.
    7. Pivonkova, H. et al. (2010) Neurochem. Int. 57, 783.
    8. Bocksteins, E. et al. (2009) Am. J. Physiol. 296, C1271.
    9. Howorth, P.W. et al. (2009) J. Neurosci. 29, 12855.
    10. Shan, H. et al. (2009) Br. J. Pharmacol. 158, 1227.
    11. Hinard, V. et al. (2008) Development 135, 859.
    12. Narazaki, G. et al. (2008) Circulation 118, 498.
    13. Vit, J.P. et al. (2008) J. Neurosci. 28, 4861.
    14. Yanagi, K. et al. (2007) Stem Cells 25, 2712.
    15. Gavillet, B. et al. (2006) Circ Res. 99, 407.
    16. Grishin, A. et al. (2006) J. Biol. Chem. 281, 30104.
    17. Gaborit, N. et al. (2005) Circulation 112, 471.
    18. Melnyk, P. et al. (2005) Cardiovasc. Res. 65, 104.
    19. Dhamoon, A.S. et al. (2004) Circ. Res. 94, 1332.
    20. Malinowska, D.H. et al. (2004) Am. J. Physiol. 286, C495.
    21. Yan, L. et al. (2004) Diabetes 53, 597.
    22. Karkanis, T. et al. (2003) Am. J. Physiol. 284, H2325.
    23. Vicente, R. et al. (2003) J. Biol. Chem. 278, 46307.
    24. Ennis, I.L. et al. (2002) J. Clin. Invest. 109, 393.
    25. Giovannardi, S. et al. (2002) J. Biol. Chem. 277, 12158.
    26. Trepanier-Boulay, V. et al. (2001) Circ Res 89, 437.
    27. Keren-Raifman, T. et al. (2000) Biochem. Biophys. Res. Commun. 274, 852.
    Shipping and Ordering information